Meet Anj, Breast Cancer Survivor and Signatera Patient

Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient

Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

MRD in a minute: Marcus Noel, MD

MRD in a minute: Marcus Noel, md

MRD in a minute: Saum Ghodoussipour, MD

MRD in a minute: Saum Ghodoussipour, md

MRD in a minute: John Sfakianos, MD

MRD in a minute: John Sfakianos, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, MD

MRD in a minute: Caroline Koffke, bsn, rn

MRD in a minute: Caroline Koffke, BSN, RN

MRD in a minute: Signatera™ Genome

MRD in a minute: Signatera™ Genome CC

MRD in a minute: Changing how cancer is managed

MRD in a minute: Changing how cancer is managed

Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing